Compare IDEXX Laboratories, Inc. (IDXX) vs Tripadvisor Inc Common Stock (TRIP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Tripadvisor Inc Common Stock — how do they compare? IDEXX Laboratories, Inc. trades at $552.09 (market cap $44.48B), while Tripadvisor Inc Common Stock trades at $13.89 (market cap $1.68B). The key difference: IDEXX Laboratories, Inc. is far larger — about 26.5× Tripadvisor Inc Common Stock's market cap, and Tripadvisor Inc Common Stock is trading nearer its 52-week high, IDEXX Laboratories, Inc. nearer its low. Which is the better fit depends on your goals.
| IDXX | TRIP | |
|---|---|---|
Market Cap | $44.48B | $1.68B |
Sector | Health | Consumer Cyclical |
52-Week High | $766.68 | $19.14 |
52-Week Low | $520.87 | $9.24 |
Enterprise Value | $45.38B | $1.80B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDXX trades at $563.79, down 0.64% today but maintains strong fundamental momentum with consistent earnings beats and robust profitability. The stock shows bullish technical signals with support at $563 and resistance at $572, while valuation metrics remain elevated. Recent Q1 2026 results exceeded expectations with EPS of $3.47 versus $3.41 estimates, supporting the company's leadership in veterinary diagnostics.
Outlook remains positive given strong analyst support (59% buy ratings) and innovation pipeline, though premium valuations and competitive pressures present risks. Revenue growth trajectory and expanding margins provide fundamental support for continued upside potential in the pet healthcare sector.
Tripadvisor (TRIP) trades at $14.38, down 1.37% with mixed technical signals showing bullish moving averages but neutral oscillators. The company reported Q1 2026 earnings miss but maintains strong gross margins of 91.95%. Recent $700 million sale of TheFork to American Express provides capital flexibility while focusing on core travel experiences business. Revenue growth remains modest at $1.89B in 2025 with net margin improving to 2.11%.
Outlook remains cautious with analyst consensus at Hold (60.72%) and $13.87 price target below current levels. The stock faces headwinds from competitive pressures and macroeconomic uncertainty, though the strategic divestiture and travel recovery trends offer potential upside. Key risks include execution challenges and market volatility amid mixed earnings performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Tripadvisor Inc Common Stock
TripAdvisor is the world's leading travel metasearch company. The website offers 1 billion reviews and information on about 8 million accommodations, restaurants, experiences, airlines, and cruises. In 2021, 74% of revenue came from the company's core segment, which includes hotel revenue generated through advertising on its metasearch platform. Viator, its experiences brand, was 20% of sales in 2021, and TheFork, its dining brand, represented 9% of revenue (about 3% of sales were intersegment, which are eliminated from consolidated revenue).
Read more on TRIP →
